Liver disease as an adverse event for men on ADT

A newly published article in the Journal of Urology has indicated risk of an association between treatment with androgen deprivation therapy (ADT) and risk for a spectrum of liver disorders. … READ MORE …

Common long-term side effects of ADT in treatment of prostate cancer

A new analysis of data from men treated for their prostate cancer between 1992 and 2009 has provided additional information with respect to risks for long-term side effects of androgen deprivation therapy (ADT). … READ MORE …

Risk for DVT and PE as a complication of treatment with ADT

A newly published paper in Prostate Cancer and Prostatic Diseases has confirmed that there is an association between specific forms of androgen deprivation therapy (ADT) and certain types of adverse thromboembolic events. … READ MORE …

Metformin + ADT in treatment of advanced prostate cancer

Yet another study, just published in the Journal of Urology, has indicated a clear association between the use of metformin along with androgen deprivation therapy (ADT) in the treatment of advanced forms of prostate cancer. … READ MORE …

A prostate cancer book that is uniquely useful

There is a large number of books for patients that deal with a diagnosis and management of prostate cancer. However, there is a relatively small number of books that are really valuable for a large number of men (and their partners) who have to deal with a diagnosis of prostate cancer. Very few books on prostate cancer ever make it into a second edition. … READ MORE …

Short-term ADT for men on active surveillance?

One paper to be presented at the upcoming annual meeting of the American Urological Association (AUS) gives results from treatment with a 3-month dose of androgen deprivation therapy (ADT) for men with low-risk prostate cancer compared to standard active surveillance. … READ MORE …

Adjuvant mitoxantrone + prednisone + ADT in treatment of high-risk prostate cancer

About 25 years ago the addition of the combination of mitoxantrone + prednisone to androgen deprivation therapy (ADT) was the first form of chemotherapy ever approved for the treatment of metastatic, castration-resistant prostate cancer. … READ MORE …